ORP-101
| Identifiers | |
|---|---|
| CAS Number | |
| PubChem CID | |
| UNII | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Chemical and physical data | |
| Formula | C60H84N2O8 |
| Molar mass | 961.3 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ORP-101 is a drug developed by OrphoMed for the treatment of diarrhea predominant Irritable Bowel Syndrome. The compound is characterized as a metabolically stable, peripherally active Buprenorphine-Dimer which acts as a partial mu-opioid agonist and full kappa-opioid antagonist. In multiple animal models ORP-101 has repeatedly been shown to significantly decrease fecal output, suppress general and colon-specific hyperalgesic signals without CNS penetration and without constriction of the sphincter of Oddi.[1][2]
The compound has entered Phase 2 clinical trials in the United States (NCT04129619) and is projected to enroll 320 participants in the Double-Blind, Placebo-Controlled, Responsive Adaptive Randomized study.[3]
In April 2018 ORP-101 received the Fast Track Designation from the FDA.[4]
See also
References
- ↑ "ORP-101 | Motility Dysfunction in IBS-D | OrphoMed, Inc". www.orphomed.com. Retrieved 2019-12-31.
- ↑ "Events and Presentations for OrphoMed, Inc". www.orphomed.com. Retrieved 2019-12-31.
- ↑ "A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-12-31.
- ↑ "FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D". www.orphomed.com. Retrieved 2019-12-31.
This article "ORP-101" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:ORP-101. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
